IMPORTANCE Approximately 50% of the risk for the development of testicular germ cell tumors (TGCTs) is estimated to be heritable, but no mendelian TGCT predisposition genes have yet been identified. It is hypothesized that inherited pathogenic DNA repair gene (DRG) alterations may drive susceptibility to TGCTs.
T esticular germ cell tumors (TGCTs) are the most common malignant neoplasms in young males. 1, 2 Family and twin studies have shown that TGCTs have a strong inherited genetic component with an estimated heritability of 48.9%, making TGCTs far more heritable than breast, ovarian, and colorectal cancers. 3 Despite this high heritability and familial tendency, to our knowledge, no highly penetrant mendelian TGCT predisposition genes have been identified. 4 Moderate-risk and low-risk single-nucleotide polymorphisms, identified through genome-wide association studies, are thought to explain only 37% of father-to-son familial risk, leaving most TGCT heritability yet to be elucidated. 3, [5] [6] [7] A previous study explored the origins of TGCTs by conducting an integrative analysis of tumor genomic and transcriptomic data, showing that TGCTs were exceptionally enriched for arm-level and chromosome-level gains of 1 parental allele with simultaneous loss of the other parental allele, leading to reciprocal loss of heterozygosity. 8 This DNA double-strand break-enriched genomic signature suggested that increased DNA damage with deficient repair might be central to the development and progression of TGCTs. This notion is further supported by genome-wide association studies that highlighted several validated TGCT-risk single-nucleotide polymorphisms located in or near DNA-damage sensing and repair genes, such as RAD51C and RFWD3. 9 However, the role of inherited DNA repair defects in TGCT pathogenesis is largely uncharacterized. We hypothesized that germline pathogenic variants in DNA repair genes (DRGs) that have been associated with susceptibility to other cancer types 10 might be associated with a predisposition to TGCTs. To evaluate this hypothesis, we conducted a multistage case-control analysis to systematically evaluate germline pathogenic variants in 48 Mendelian cancerpredisposition DRGs in unselected 205 men with TGCT compared with 27 173 cancer-free non-Finnish European individuals from the Exome Aggregation Consortium (ExAC) cohort. Significant findings from the discovery phase were replicated in independent cohorts of 448 unselected men with TGCTs and 442 population-matched controls, as well as 231 high-risk men with TGCTs and 3090 cancer-free men.
Methods

Study Participants
A total of 205 individuals with TGCT were included in the discovery cohort (eFigure 1 in Supplement 1) from 2012 to 2017. These men were not specifically selected for early-onset disease or a positive family history of TGCTs and are hereafter referred to as unselected. In addition, we used the cancerfree non-Finnish European individuals of the ExAC cohort, excluding the TCGA cases, as a discovery control group (n = 27 173; hereafter referred to as the ExAC NFE cohort).
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In the validation phase, germline data of independent cohorts of 448 unselected Croatian men with TGCTs (hereafter referred to as the Croatian cohort) and 442 populationmatched cancer-free men were examined. Germline data of another 231 men with TGCTs who came from families with 2 or more individuals with TGCTs or those with bilateral TGCTs (hereafter collectively referred to as the high-risk TGCT cohort) and an ancestry-matched group of 3090 cancer-free men ascertained from the Penn Medicine Biobank were also examined (eFigure 1 in Supplement 1). This study was approved by the participating institutions (Dana-Farber Cancer Institute, National Cancer Institute, and University of Pennsylvania) (eAppendix in Supplement 1). All individuals in the discovery, validation, and high-risk cohorts provided written consent to institutional review board-approved protocols that allowed for comprehensive genetic analysis of germline samples. This study conforms to the Declaration of Helsinki. 12 
Population Stratification
In the discovery phase, principal component analysis was first performed on high-quality nonlinked germline genotypes of 239 individuals with TGCT and a reference group of 938 individuals from the 1000 Genomes Cohort (eAppendix and eFigures 2-4 in Supplement 1).
of the examined DRGs. P < .05 was considered significant. Top candidate genes, with a false discovery rate of less than 0.05 in the discovery cohort, were selectively evaluated in independent TGCT cohorts. Regression models were used to examine the association between the germline mutational status and the clinical characteristics of individuals with TGCTs (eAppendix in Supplement 1).
Results
Characteristics and Sequencing Metrics of Discovery TGCT Cohort
The demographic characteristics of all individuals with TGCTs in our study are summarized in eTable 2 and eFigure 5 in Supplement 1 and the eTable in Supplement 2. The exomewide median target coverage for germline whole-exome sequencing for the discovery cohort samples was 67.24X (interquartile range, 51.97-77.92) (eFigure 6A in Supplement 1). The median sequencing depth of coverage for the examined DRGs (n = 48) was 133.5X (interquartile range, 119.7-151.6) in the discovery TGCT cohort and 59.63X (interquartile range, 54.45-65.36) in the ExAC cohort (eTable 3 in Supplement 1). All samples had satisfactory exome-wide variant call rates, variant transition-to-transversion rates, and genotype quality (eFigures 6B-F in Supplement 1).
Germline Pathogenic DRG Variants in Discovery Cohort
In the discovery cohort (n = 205), 20 men with TGCTs (9.8%; 95% CI, 6.1%-14.7%; binomial exact) had germline pathogenic variants ( Figure 1A ). Figure 1B ). In addition, 2 men with TGCTs (1.0%) carried 1 heterozygous pathogenic variant in CHEK2 plus a second pathogenic variant in NBN (OMIM 602667)orFANCD2 (eTable 4 in Supplement 1). .05
<.001
A, A total of 22 pathogenic germline variants in 20 of 205 men with TGCTs (9.8%) were seen in 10 of the examined DRGs. Two individuals had 2 pathogenic DRG variants each. B, Most of the detected germline pathogenic variants were truncating in nature (ie, frameshift, nonsense, or canonical splice-site variants). C, Gene-based enrichment analysis of the detected pathogenic alterations in 205 unselected individuals with TGCTs relative to 27 173 cancer-free ancestry-matched individuals from the Exome Aggregation Consortium cohort. Error bars indicate 95% CIs. D, Applying a false discovery rate of less than 0.05 for significance, only CHEK2 showed significant enrichment of pathogenic loss-of-function (LOF) variants in the discovery TGCT cohort, which was subsequently validated in independent TGCT cohorts.
Research Original Investigation Association of Inherited Variants in CHEK2 With Susceptibility to Testicular Germ Cell Tumors
For each of the examined DRGs (n = 48), we compared the frequency of pathogenic germline variants in 205 European men with TGCTs from the discovery cohort with the frequency of these genetic alterations in 27 173 cancer-free European controls. Using a false discovery rate q value of less than 0.05 for significant associations, our case-cohort analysis of the TGCT discovery cohort showed significant pathogenic variant enrichment in CHEK2 ( Figure 1C and Table) .
Germline Pathogenic CHEK2 Variants in Discovery Cohort
Approximately one-third (8 [36.4%]) of the 22 detected pathogenic DRG variants were in CHEK2, the most commonly mutated gene in the discovery TGCT cohort ( Figure 1D ). Among 8 men with TGCTs (3.9%) with pathogenic CHEK2 germline variants, 6 (2.9%) carried variants known to cause complete loss of function (LOF) either by protein truncation (n = 5) or by amino acid substitution in a critical functional domain leading to abolished CHEK2 kinase activity (n = 1). 14, 15 In addi- (Figure 2A ; Table) . Our analysis also showed a statistically insignificant enrichment of CHEK2 p.Ile157Thr in the discovery cohort of individuals with TGCTs vs controls (OR, 1.15; 95% CI, 0.20-4.39; false discovery rate of 0.21) ( Figure 2B ; Table) . 
Cohort
A, Analysis of the genomic data showed that individuals with TGCTs from the discovery (n = 205), the Croatian (n = 448), and the high-risk (n = 231) cohorts were significantly more likely to carry a germline CHEK2 loss-of-function (LOF) variant compared with ancestry-matched controls (odds ratio (OR), 3 Figure 4 .
Discussion
Testicular germ cell tumors are one of the most heritable cancers. 3 However, the inherited genomic drivers of TGCT initiation and progression are not fully characterized. Here, we build on our findings of increased DNA double-strand breaks as a unique genomic feature for TGCTs and identify inherited pathogenic DRG variants as potential genomic determinants of TGCT susceptibility in 3 large independent unselected and high-risk TGCT cohorts. Our systematic discovery case-cohort analysis of deleterious variants in 48 Mendelian cancer-risk DRGs in 205 unselected European men with TGCTs and 27 173 cancer-free European individuals from the ExAC cohort showed a significantly higher than expected rate of inherited CHEK2 pathogenic variants in men with TGCTs. CHEK2 encodes a 543-residue protein kinase (CHEK2) that is phosphorylated by the DNA damage-sensing protein ATM (ataxia-telangiectasia mutated) to subsequently regulate more than 20 downstream effector proteins, including BRCA1, BRCA2, p53, and
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Association of Inherited Variants in CHEK2 With Susceptibility to Testicular Germ Cell Tumors Rb, which are critical for DNA double-strand break repair, 20 cell cycle regulation, 21 and cellular apoptosis. 22 Germline LOF mutations in CHEK2 are known to confer an increased susceptibility to breast, prostate, and colorectal cancers. [23] [24] [25] However, no study so far, to our knowledge, has evaluated the prevalence and significance of pathogenic CHEK2 variants, or those affecting other DRGs, in individuals with TGCTs. We have shown that carriers of germline LOF alterations in CHEK2 from all unselected and high-risk cohorts were significantly more likely to develop TGCTs compared with male carriers of the wild-type CHEK2 allele. In addition, we also delineated the association of CHEK2 p.Ile157Thr in men with TGCTs. CHEK2 p.Ile157Thr is a European founder missense variant that is present in up to 5% of cancer-free individuals from isolated populations in Poland, Finland, and Croatia. 26 Functional studies have demonstrated that isoleucine-to-threonine substitution at position 157 impedes CHEK2 homodimerization in a dominant negative manner. 27 As a result, CHEK2 p.Ile157Thr results in a modest increase in the risk of breast cancer (OR, 1.6) and colorectal cancer (OR, 1.4). cohort was large enough to be adequately powered to detect such a modest increase in the risk of TGCTs. In the Croatian population, CHEK2 p.Ile157Thr is a common founder variant (population frequency, approximately 1%-2%) that, similar to CHEK2 LOF variants, appears to confer an increased risk of TGCTs. Larger studies in such genetically unique populations are still needed to confirm this observation. Collectively, our analysis supports germline pathogenic variants in CHEK2 as novel inherited genomic modifiers of susceptibility to TGCT. To our knowledge, CHEK2 is the only Mendelian TGCT predisposition gene that has so far been identified, which carries both mechanistic and clinical importance. Mechanistically, our findings complement a growing body of evidence for CHEK2 as a master regulator of chromosomal segregation, DNA damage repair, and cell cycle regulation during germ cell development and maturation. A study by Bartkova et al 29 noted that CHEK2 expression was temporarily downregulated during the meiotic stages of spermatogenesis, when programmed DNA double-strand breaks are known to occur, suggesting that CHEK2 is essential for DNA damage-induced apoptosis. Other groups have also found that, in contrast to the wild-type oocytes in which apoptosis occurs in response to widespread radiation-induced DNA double-strand breaks, Chek2-deficient mice oocytes escaped apoptosis and accumulated a substantial amount of DNA damage. 30 Finally, it has been shown that healthy germ cells lose CHEK2 expression as they progress to invasive TGCTs. 29 Our current analysis implied a particular clinical TGCT phenotype in germline CHEK2 LOF carriers, suggesting a potential distinct genomic evolution of TGCTs in the presence of inherited partial CHEK2 deficiency. Clinically, germline LOF alterations in CHEK2 confer a moderate increase in the risk of TGCTs in approximately 4% of men with TGCT and, at least partially, explain these individuals' higher risk of TGCTs. Beyond the potential for TGCT risk stratification, the identification of pathogenic germline CHEK2 variants in men with TGCTs could be informative for the clinical management of these individuals. First, men with TGCTs who carry germline CHEK2 LOF variants present significantly earlier than those with sporadic TGCTs. Furthermore, individuals with CHEK2-mutated TGCTs are more likely to develop prostate and colorectal cancers, for which specific cancer screening strategies exist. In addition, as several studies exploring the efficacy of targeted therapeutic interventions (such as CHEK1 and CHEK2 inhibitors) in DNArepair-proficient and DNA-repair-deficient tumors are under way, our study identified potentially targetable DNA-repair defects that might be exploited in chemotherapy-resistant testicular cancers.
Our study also highlights the robustness of the targeted multistage germline analysis approach to explore novel rare Mendelian cancer predisposition variants that would otherwise be extremely difficult to identify using a single-cohort exome-wide approach. 25, 31 A recent large study that explored germline coding variants in 919 men with TGCTs and 1609 cancer-free controls failed to identify major TGCT risk genes.
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Despite the large cohort size, that single-cohort study showed no statistically significant association once corrected for the 1.08 million associations that were conducted. In addition, no other independent cohorts were available to investigate the top nonsignificant candidates. Finally, that study also reported exceptionally low rates of germline CHEK2 LOF variants, rendering the study underpowered to detect genetic risk factors with an OR smaller than 10, as the authors indicated in a recent reanalysis 4 (eFigure 9 in Supplement 1). 
Limitations
Our study has several limitations. First, the raw genomic and clinical data for the ExAC cohort were not available for analysis, thus limiting our ability to control for potentially relevant variables. This limitation, however, was mitigated by validating our findings in independent cohorts for which genomic data were properly jointly genotyped and analyzed. Second, to achieve a robust population stratification, our study included only individuals with European ancestry. The frequency of these alterations, their penetrance, and the diagnostic yield of genetic testing may, however, vary substantially across genetically distinct populations. Also, insertion and deletion variants were not individually validated, although an orthogonal sequencing method (Sanger sequencing) was used to validate these findings in the replication phase. Finally, the 3 constituent studies were not designed prospectively to address this specific hypothesis, which may introduce unknown biases at the time of a pooled data analysis; hence, larger studies are still needed to further delineate this association.
Conclusions
Our 
eAppendix. Methods
Study subjects 1-Discovery cohort: A total of 239 men with TGCT were evaluated in the study discovery phase. These persons came from three independent cohorts: the Cancer Genome Atlas (TCGA; n=150), the Dana-Farber Cancer Institute (DFCI) TGCT cohort (n=49) 1 , and the TGCT cohort described by Litchfield et al., 2014 of the United Kingdom (UK) Institute for Cancer Research (ICR) (n=40, hereafter called the ICR cohort) 2 . Of the initial 239, only individuals with high-quality sequencing data who matched the European ancestral genetic cluster, using principal components analysis (PCA), were included in this study (n=205; eFigures 1 & 2). Men with TGCT were not specifically selected for early-onset disease or a TGCT family history (hereafter referred to as "unselected"). This study was approved by the DFCI IRB (#10-025). In the discovery phase, we also used the cancer-free non-Finnish European individuals of the Exome Aggregation Consortium (ExAC) cohort as a control group (n=27,173; hereafter called ExAC NFE). All persons with cancer diagnoses (i.e., the TCGA cohort) were excluded from the ExAC NFE control cohort. Raw germline sequencing data from this cohort were not available. However, the variant calling file (VCF), containing minor allele frequencies and other annotations of all cohort germline genetic variants, was available for evaluation (ExAC release 0.3.1, on 3/16/2016).
2-Croatian validation cohort:
Germline data of an independent cohort of 448 unselected Croatian men with TGCTs were evaluated in the validation phase of this study. These participants were ascertained from the Clinical Hospital Center in Zagreb, Croatia (hereafter called the "Croatian cohort"). In addition to men with TGCT, a total of 442 male healthy controls from the Croatian population, who were at least 50 years old with no personal or family history of cancer, were sequenced as previously described (eFigure 1) 3 . All participants provided written informed consent. This study was approved by the Clinical Hospital Center Zagreb IRB (#8.1-10/115-2), the Croatian Institute for Transfusion Medicine, and the University of Ulm, Germany.
3-High-risk TGCT cohort:
To delineate the penetrance of DRG variants in high-risk TGCTs, we evaluated germline whole exome sequencing data of a third independent cohort of 231 TGCT participants who came from families with two or more confirmed TGCT subjects or those with bilateral TGCTs (hereafter collectively called the "High-risk TGCT cohort"). Germline DNA, derived from Blood or saliva, of these affected persons were obtained through the "Multidisciplinary Etiologic Study of Familial Testicular Cancer" (NCI Protocol 02-C-0178) 4, 5 , or through a population-based study in the Philadelphia region as previously reported 6 . In addition, we compared these individuals with a control cohort of 3,090 cancer-free males from the Penn/NCI Medicine BioBank (PMBB), through which individuals provided blood for DNA and consented to phenotypic data collection using their electronic health record (EHR). Control individuals were selected based on European ancestry (using PCA), age 60-90 years, male by both EHR identification and 46,XY genotyping, and absence of a personal history of malignant or benign tumors (eFigure 1).
Population stratification: In the discovery phase, principal component analysis (PCA) was first performed on high-quality nonlinked germline genotypes of 239 TGCT individuals and a reference group of 938 individuals from the 1,000 Genomes Cohort (eFigures 2A & 2B). Using the ancestry information of the 1000 genomes cohort as a truth set, a clustering algorithm (with K-means) was run on the first three principal components of both cohorts to classify the discovery TGCT individuals into seven continental populations (Africa, America, Central/South Asia, East Asia, Europe, Middle East, and Oceania) as defined by the 1,000 Genomes Project 7 . Of 239 TGCT persons who were initially evaluated, 206 individuals mapped to the European cluster and were subsequently evaluated for sequencing quality control (see Quality Control). To minimize spurious associations that might result from comparing cohorts from different ancestral populations, TGCT persons from non-European ancestries (n=33) were excluded from the discovery phase analysis (eFigure 2C). Similarly, only the non-Finnish European subgroup of the ExAC cohort (ExAC NFE), which also mapped to the European PCA cluster, was used as a control group 8 . Frequencies of population-informative common SNPs were similar in persons with TGCTs and controls, minimizing the likelihood of a hidden unbalanced population structure between the TGCT discovery analysis cohorts (eFigure 3).
For the Croatian TGCT cohort (validation phase), persons with and without TGCT were ascertained from the same population with no preselection except for the disease-of-interest status, as previously described 3 . Similar to the discovery cohort, high-risk TGCT cohort (n=231) and its control group (n=3,090) were evaluated using PCA analysis to ensure homogenous genetic architecture in both groups. Only men falling within the 1,000 genomes European PCA cluster were included in this analysis.
Sequencing and bioinformatics analysis Briefly, germline DNA from the discovery TGCT cohort was obtained from blood or adjacent normal testicular tissue dissected after pathology review. DNA was extracted from formalin-fixed, paraffinembedded (FFPE) blocks as previously described 9 . Whole-exome capture libraries were constructed from normal DNA after sample shearing, end repair, phosphorylation, and ligation to barcoded sequencing adaptors 9 . DNA reads were captured using SureSelect v.2 Exome bait (Agilent Technologies) and sequenced on Illumina HiSeq 2000. The sequencing and bioinformatics pipelines used to generate the raw germline genomic data for the TCGA and ICR cohorts have been described elsewhere 1, 2, 10 .
For the Croatian TGCT and cancer-free persons (n=448 and 442, respectively), Sanger sequencing of CHEK2 was performed on germline DNA extracted from peripheral blood 11 . Given the substantial homology with several pseudogenes, the last five exons of CHEK2 (exons 10-14) were analyzed using a long-range PCR protocol. In addition, Multiplex Ligation-dependent Probe Amplification (MLPA; SALSA MLPA P190 CHEK2 probemix; MRC-Holland) was used on genomic DNA of affected individuals and healthy controls to evaluate CHEK2 copy number variation.
Exome capture from germline DNA isolated from blood or saliva was done on the high-risk TGCT cohort using SureSelect liquid-based hybrid capture system from Agilent Technologies with paired-end sequencing on an Illumina Hi-Seq 4000 (2 × 150 bp) (UPENN/NCI protocol) or NimbleGen SeqCap EZ probes. Captured, multiplexed DNA pools were PCR-amplified and quantified with the Kapa Library Quantification Kit and sequenced on either an Illumina HiSeq 2000 or HiSeq 2500 platforms (2x100bp or 2x125bp) (NCI protocol). Copy number variations identified through exome bioinformatic analysis were confirmed using an MLPA protocol, as above.
Quality control Germline raw sequencing data of the examined TGCT individuals were evaluated using established quality control measures such as depth of coverage, call rate, genotype and sample quality scores. Samples with a mean depth of coverage under 50X for the examined DRGs or those with a sample mean call rate of < 0.9 were excluded. One sample was excluded due to low sequencing coverage, yielding a total of 205 persons with TGCT in the final discovery cohort (eFigure 4). All samples in the Croatian and high-risk TGCT cohorts had satisfactory quality metrics.
Germline variant discovery Germline whole exome sequencing data of the discovery cohort were used to perform germline variant calling of single nucleotide variants (SNVs) and small deletions/duplications (indels) across all samples. Genome Analysis Toolkit (GATK) HaplotypeCaller pipeline (version 3.7) was used to call germline variants according to the GATK best practices 12 . GATK Variant Quality Score Recalibration (VQSR) method was used to filter germline variants. The SNP VQSR model was trained using HapMap3.3 and 1KG Omni 2.5 SNP sites, and a 99.6% sensitivity threshold was applied to filter variants. In addition, Mills et. al. 1KG gold standard and Axiom Exome Plus sites were used for indel recalibration using a 95% sensitivity threshold, similar to the threshold used for the ExAC cohort analysis 8, 13 . In addition to focal germline variants, germline copy number alterations were evaluated using the bioinformatics package "CODEX", as previously described 14 . The same variant calling pipeline was used to identify germline focal and copy number variants from WES data of the high-risk TGCT individuals and their control cohort. For men with and without TGCT in the Croatian validation cohort, germline variants were called from the Sanger sequencing and MLPA data, as previously described 15 .
Functional annotation Germline variant annotation was performed using SnpEff (version 4.3) for the discovery cohort and ANNOVAR for in the Croatians and high-risk TGCT cohorts [16] [17] [18] . Only variants impacting the canonical transcript of the gene were included.
Selection of DNA-repair genes Although hundreds of genes are known to be involved in the DNA damage response machinery, only DNA-repair genes with validated evidence of Mendelian cancer susceptibility in humans (n=48) were examined in the discovery phase (eTable 1). Genes with significant pathogenic variant enrichment in the discovery phase were then selectively examined in the validation phase. In addition to the 48 established cancer-risk DRGs that were examined in the discovery cohort, we defined a subset of those genes as "clinically actionable". Clinically actionable genes are DRGs that confers an increased inherited susceptibility to cancers other than TGCT and for which specific management recommendations do exist (eTable 9).
Germline variant pathogenicity evaluation Pathogenicity of the detected germline variants in persons with TGCT and respective controls across all cohorts was classified using the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) clinically-oriented guidelines 19 . Germline variants in case and control cohorts were independently evaluated for pathogenicity by three clinical geneticists against the published literature and publicly-available databases such as ClinVar and gene-specific databases. Population minor allele frequencies were extracted from publicly-available databases such as the Exome Aggregation Consortium (ExAC) and the Genome Aggregation Database (gnomAD) 8 . Based on the available evidence, germline variants were classified into 5 categories: benign, likely benign, variants of unknown significance, likely pathogenic and pathogenic 20 . Only germline variants which had sufficient evidence of pathogenicity to be classified as pathogenic or likely pathogenic variants were included in this study (hereafter collectively referred to as pathogenic germline variants). Variants of unknown significance (VUSs) were excluded from all analyses.
Pathogenic CHEK2 variant frequency and TGCT prevalence in genetically distinct populations: To examine the frequency of pathogenic CHEK2 variants in the European, African and North European (Danish) cohorts, we examined the frequency of the most common CHEK2 LOF variant, c.1100delC, reported in previously published studies 21 as well as in the ExAC cohort 8 . For the frequency of TGCTs in these population, we used estimates from previously published studies 21, 22 .
Statistical Analysis Two-sided Fisher's exact tests were used to calculate the odds ratios and confidence intervals (using "minimum likelihood correction") for the enrichment of germline pathogenic variants in each of the examined DRGs. In addition, two-sided binomial exact test was used to calculate the P value for the measured variant enrichment of each gene in the discovery cohort compared with the reference population (ExAC NFE). Consistent with established statistical methods for multi-stage association studies, we implemented a permissive discovery stage analysis in which genes with a false discovery rate (FDR) <0.05 were considered significant. Top candidate genes were then selectively evaluated in independent population-based and high-risk TGCT cohorts, prior to performing secondary analyses, using a two-sided Fisher's exact test with correction for multiple testing using Bonferroni correction when applicable [23] [24] [25] . Lastly, a logistic regression model was used to examine the association between germline mutational status and clinical characteristics of TGCT individuals. Linear regression models were also used to assess the association between the "age at diagnosis" and CHEK2 mutational status. Statistical analyses were done using "exact2x2" (version 1.5.2) and "stats" (version 3.3.1) packages on R (version 3.3.1), SAS (version 9.4), and Stata (version 14.1).
eFigure 1. TGCT Cohorts Examined in This Study
In the discovery phase, germline variants in 48 cancer-predisposition DNA repair genes were examined in a total of 205 European TGCT patients and control individuals from the same population. Genes, where significant pathogenic germline variant enrichment was seen in the discovery cohort, were then examined in 448 unselected Croatian TGCT patients and 231 high-risk TGCT patients and population-specific control cohorts. 
